Bullish Case: ALPHA3's 58%-vs-16% MRD advantage remains unrefuted, and Helium's price density retains a thin right tail at $1.5-2.0 (density 0.15-0.07 vs modal $1.0). At $1.09, downside is partially anchored by the Nov 20 and Feb 19 1.50C/1.00P structures showing Helium model values near bid/ask — if a durability update lands clean before the mid-2027 readout, short-covering off a -94.6% five-year drawdown could reprice quickly.

Bearish Case: The return surface concentrates likelihood in modest losses across horizons; Helium's density peaks at $1.0 (0.53) with heavier mass below spot than the market curve (0.25 vs 0.22 at $0.5). A -44.7% ninety-day slide, CFO insider selling, Caribou's allogeneic CAR-T exit (October 6), and put IVs at 200-500% signal survival/dilution fear. Cash burn toward a likely raise keeps sub-$1.00 tails live.

Potential Outcomes:

1. 35% Grind $0.85-$1.30: no catalyst, dilution overhang; falsified by >$1.50 reclaim (Jun base case already falsified at $1.09).
2. 25% Financing (ATM/follow-on) disclosed → $0.70-$1.00; falsified by no 424B by Mar 2027.
3. 18% Positive ALPHA3/ALLO-316 durability update → $1.60-$2.20; falsified if MRD <30% or Grade3+ CRS/ICANS.
4. 12% Safety/futility signal → <$0.75.
5. 6% Partnership/deal → >$1.80.
6. 4% SPY risk-off derating (-20%+).

November 04, 2026